ES2897666T3 - Compuestos de aminopirimidina útiles como inhibidores de SSAO - Google Patents

Compuestos de aminopirimidina útiles como inhibidores de SSAO Download PDF

Info

Publication number
ES2897666T3
ES2897666T3 ES18706109T ES18706109T ES2897666T3 ES 2897666 T3 ES2897666 T3 ES 2897666T3 ES 18706109 T ES18706109 T ES 18706109T ES 18706109 T ES18706109 T ES 18706109T ES 2897666 T3 ES2897666 T3 ES 2897666T3
Authority
ES
Spain
Prior art keywords
mmol
mixture
methyl
pharmaceutically acceptable
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18706109T
Other languages
English (en)
Spanish (es)
Inventor
Mengyang Fan
Luoheng Qin
Yi Wei
Guoqiang Zhou
Jingye Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63169081&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2897666(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2897666T3 publication Critical patent/ES2897666T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES18706109T 2017-02-14 2018-02-07 Compuestos de aminopirimidina útiles como inhibidores de SSAO Active ES2897666T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2017/000157 WO2018148856A1 (en) 2017-02-14 2017-02-14 Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors
PCT/CN2017/117791 WO2018149226A1 (en) 2017-02-14 2017-12-21 Amino pyrimidine compounds useful as ssao inhibitors
PCT/US2018/017152 WO2018151985A1 (en) 2017-02-14 2018-02-07 Amino pyrimidine compounds useful as ssao inhibitors

Publications (1)

Publication Number Publication Date
ES2897666T3 true ES2897666T3 (es) 2022-03-02

Family

ID=63169081

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18706109T Active ES2897666T3 (es) 2017-02-14 2018-02-07 Compuestos de aminopirimidina útiles como inhibidores de SSAO

Country Status (13)

Country Link
US (2) US10278970B2 (US20070167479A1-20070719-C00034.png)
EP (1) EP3582780B1 (US20070167479A1-20070719-C00034.png)
JP (2) JP7030827B2 (US20070167479A1-20070719-C00034.png)
KR (1) KR20190117007A (US20070167479A1-20070719-C00034.png)
CN (2) CN114369095A (US20070167479A1-20070719-C00034.png)
AU (1) AU2018221322B2 (US20070167479A1-20070719-C00034.png)
CA (1) CA3052044A1 (US20070167479A1-20070719-C00034.png)
DK (1) DK3582780T3 (US20070167479A1-20070719-C00034.png)
ES (1) ES2897666T3 (US20070167479A1-20070719-C00034.png)
IL (1) IL268625A (US20070167479A1-20070719-C00034.png)
MX (1) MX2019009501A (US20070167479A1-20070719-C00034.png)
SG (2) SG11201907032RA (US20070167479A1-20070719-C00034.png)
WO (3) WO2018148856A1 (US20070167479A1-20070719-C00034.png)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
WO2018148856A1 (en) 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors
CN109251166B (zh) * 2017-07-13 2021-11-05 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
CN109810041B (zh) * 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN109988106B (zh) * 2017-12-29 2023-03-31 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
WO2020006177A1 (en) * 2018-06-29 2020-01-02 Blade Therapeutics, Inc. Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof
CN110938059A (zh) * 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
WO2020063854A1 (zh) * 2018-09-27 2020-04-02 南京明德新药研发有限公司 作为vap-1抑制剂的喹啉类衍生物
DK3873600T5 (da) 2018-10-29 2024-03-18 Boehringer Ingelheim Int Pyridinylsulfonamidderivater, farmaceutiske sammensætninger og anvendelser deraf
JP7425793B2 (ja) * 2018-10-29 2024-01-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用
JP2022517085A (ja) * 2019-01-11 2022-03-04 南京薬捷安康生物科技有限公司 ハロゲン化アリルアミン系化合物及びその適用
CN111471037B (zh) * 2019-01-23 2023-02-10 药捷安康(南京)科技股份有限公司 烯丙基胺类化合物及其应用
MX2022005199A (es) 2019-10-29 2022-08-04 Eccogene Shanghai Co Ltd Inhibidores de ssao y uso de los mismos.
CN113149957A (zh) * 2020-01-23 2021-07-23 轶诺(浙江)药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
MX2023002308A (es) 2020-08-25 2023-07-11 Lilly Co Eli Polimorfos de un inhibidor de ssao.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008123469A1 (ja) 2007-03-30 2008-10-16 Japan Tobacco Inc. 6員環アミド化合物およびその用途
AU2008280784A1 (en) 2007-07-20 2009-01-29 Merck Frosst Canada Ltd Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US8426587B2 (en) 2007-11-21 2013-04-23 Pharmaxis Ltd. Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
US20110014558A1 (en) 2009-07-15 2011-01-20 Kabushiki Kaisha Toshiba Developing agent and method for producing the same
TW201116276A (en) * 2009-09-16 2011-05-16 Astellas Pharma Inc Glycine compounds
JP2011136942A (ja) 2009-12-28 2011-07-14 Kowa Co 新規な置換ピリミジン誘導体およびこれを含有する医薬
HUE028394T2 (en) * 2011-03-15 2016-12-28 Astellas Pharma Inc Guanidin Compound
ES2668300T3 (es) * 2012-05-02 2018-05-17 Boehringer Ingelheim International Gmbh Inhibidores de SSAO de 3-haloamidina sustituida y usos de los mismos
ES2606197T3 (es) 2012-11-16 2017-03-23 Bristol-Myers Squibb Company Moduladores pirrolidina de GPR40
US8962641B2 (en) * 2013-04-17 2015-02-24 Boehringer Ingelheim International Gmbh Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof
EP2997024B1 (en) 2013-05-17 2018-03-28 Boehringer Ingelheim International GmbH Pyrrolidine derivatives, pharmaceutical compositions and uses thereof
GB201416444D0 (en) * 2014-09-17 2014-10-29 Proximagen Ltd New compounds
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
WO2018148856A1 (en) 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors

Also Published As

Publication number Publication date
SG10201913492YA (en) 2020-03-30
KR20190117007A (ko) 2019-10-15
IL268625A (en) 2019-10-31
WO2018149226A1 (en) 2018-08-23
MX2019009501A (es) 2019-11-05
AU2018221322B2 (en) 2022-04-14
JP7030827B2 (ja) 2022-03-07
SG11201907032RA (en) 2019-08-27
US20190275041A1 (en) 2019-09-12
EP3582780A1 (en) 2019-12-25
CN108778278A (zh) 2018-11-09
CN108778278B (zh) 2022-01-28
JP7247389B2 (ja) 2023-03-28
US10278970B2 (en) 2019-05-07
JP2020507589A (ja) 2020-03-12
AU2018221322A1 (en) 2019-08-15
WO2018148856A1 (en) 2018-08-23
WO2018151985A1 (en) 2018-08-23
JP2022068325A (ja) 2022-05-09
US20180296560A1 (en) 2018-10-18
CA3052044A1 (en) 2018-08-23
CN114369095A (zh) 2022-04-19
DK3582780T3 (da) 2021-11-01
US10471060B2 (en) 2019-11-12
EP3582780B1 (en) 2021-10-13

Similar Documents

Publication Publication Date Title
ES2897666T3 (es) Compuestos de aminopirimidina útiles como inhibidores de SSAO
ES2865199T3 (es) Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4
ES2908805T3 (es) Inhibidores de aminopirimidina SSAO
US10273239B2 (en) Spiro-lactam NMDA receptor modulators and uses thereof
ES2715458T3 (es) Inhibidores de dihidropirrolopiridina de ROR-gamma
US11021482B2 (en) Pyrrolopyrimidine ITK inhibitors
TWI468402B (zh) 降低β-類澱粉生成之化合物
CA3079557A1 (en) Dihydropyrimidine compounds and uses thereof in medicine
CA2935625A1 (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
US10851116B2 (en) Bicyclic amines as novel JAK kinase inhibitors
WO2017096045A1 (en) Multivalent ras binding compounds
US20130345246A1 (en) 2H-Imidazol-4-Amine Compounds and Their Use as Bace Inhibitors
KR102662205B1 (ko) 신규 plk1 분해 유도 화합물
ES2768782T3 (es) Sal de tosilato de N-r3-r(4aR,7aS)-2-amino-6-(5-fluoropirimidin-2-il)-4,4a,5,7-tetrahidropirrolo[3,4-d][1,3]tiazin-7a-il]-4-fluoro-fenil]-5-metoxi-pirazin-2-carboxamida
WO2024108009A1 (en) Dyrk/clk protacs and uses thereof